Engineered alphavirus replicon vaccines based on known attenuated viral mutants show limited effects on immunogenicity
Authors:
- Christine A. ShawCSChristine A. Shaw
- Gillis R. OttenGOGillis R. Otten
- Peter W. MasonPMPeter W. Mason
- Clayton W. BeardCBClayton W. Beard
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Nonviral delivery of self-amplifying RNA vaccinesProceedings of the National Academy of Sciences, 2012
- Modulation of type I IFN induction by a virulence determinant within the alphavirus nsP1 proteinVirology, 2010
- Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteersVaccine, 2009
- Therapeutic and prophylactic applications of alphavirus vectorsExpert Reviews in Molecular Medicine, 2008
- Early type I interferon‐mediated signals on B cells specifically enhance antiviral humoral responsesEuropean Journal of Immunology, 2006
- Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirusProceedings of the National Academy of Sciences, 2006
- Type I Interferons Trigger Systemic, Partial Lymphocyte Activation in Response to Viral InfectionThe Journal of Immunology, 2005
- Selection of Functional 5′ cis -Acting Elements Promoting Efficient Sindbis Virus Genome ReplicationJournal of Virology, 2004
- Cis-acting RNA elements at the 5′ end of Sindbis virus genome RNA regulate minus- and plus-strand RNA synthesisRNA, 2001
- Infection of Human Dendritic Cells by a Sindbis Virus Replicon Vector Is Determined by a Single Amino Acid Substitution in the E2 GlycoproteinJournal of Virology, 2000